Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.
ACS medicinal chemistry letters June 12, 2025 DOI: 10.1021/acsmedchemlett.5c00265 via PubMed
Summary
AI-generated from the abstractNew formulations of the psychedelic compounds DMT and 5-MeO-DMT allow injection or nasal spray delivery, bypassing the body's rapid breakdown of these drugs. These delivery methods produce fast-acting, short-lived therapeutic effects, making them suitable for controlled psychiatric treatments like depression that does not respond to standard therapies. The formulations aim to improve tolerability, ease of use, and clinical practicality.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | DMT 5-MeO-DMT |
| Topics | 5-MeO-DMT Depression DMT |
| Keywords | Entheogenic treatment Hallucinogen-assisted therapy Novel drug delivery Injectable drugs |
| Citations | 1 |
| Key finding | Parenteral and intranasal formulations of DMT and 5-MeO-DMT overcome bioavailability and metabolism limitations, enabling rapid-onset, short-duration therapeutic effects for conditions like treatment-resistant depression. |
Abstract
Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric conditions such as treatment-resistant depression while optimizing tolerability, scalability, and clinical utility.